Investor relations

The purpose of Gradientech’s Investor Relations is to continuously inform the capital market about the company’s operations and development. Here you will find press releases and financial reports as well as information about the share and corporate governance.

Rights issue 2023

Gradientech’s Board of Directors have decided to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 25.8 million. The subscription period now runs until and including 6 December 2023. Here you will find all information about the rights issue.

To the rights issue

Redeye Life Science Day 2023

Sara Thorslund (CEO), presented Gradientech and the QuickMIC System at the investor event Redeye Life Science Day on 23 November 2023.

Watch the presentation

Annual report 2022

Here you can read about significant events during the year, our target market and the strategy going forward.

To the annual report


About Gradientech

Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics that provide patients with the right dose of the right medicine at the right time.

Read more

Gradientech is an ISO13485 certified company since 2017


Gradientech AB
Uppsala Science Park
SE-751 83 Uppsala

About Gradientech

Gradientech develops, manufactures and sells innovative microfluidic products for high-quality analysis of the behavior of cells and organisms in response to gradients of biomolecules. Our aim is to pioneer life science and healthcare.

Copyright © 2023 Gradientech. All rights reserved. Gradientech, QuickMIC and CellDirector are registered trademarks or trademarks of Gradientech AB.

Next-generation antimicrobial susceptibility testing

Take a look at our E-book